**References**

[1] A. Passardi *et al.*, ‘A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial’, *J. Med. Internet Res.*, vol. 24, no. 1, p. e27349, Jan. 2022, doi: 10.2196/27349.

[2] A. Karaaslan-Eşer and S. Ayaz-Alkaya, ‘The effect of a mobile application on treatment adherence and symptom management in patients using oral anticancer agents: A randomized controlled trial’, *Eur. J. Oncol. Nurs.*, vol. 52, p. 101969, Jun. 2021, doi: 10.1016/j.ejon.2021.101969.

[3] M. B. Heneghan *et al.*, ‘Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques’, *J. Med. Internet Res.*, vol. 23, no. 2, p. e24893, Feb. 2021, doi: 10.2196/24893.

[4] A. Pereira-Salgado *et al.*, ‘Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment’, *JMIR MHealth UHealth*, vol. 5, no. 12, p. e184, Dec. 2017, doi: 10.2196/mhealth.8349.

[5] J. A. Greer *et al.*, ‘Randomized Trial of a Smartphone Mobile App to Improve Symptoms and Adherence to Oral Therapy for Cancer’, *J. Natl. Compr. Canc. Netw.*, vol. 18, no. 2, 2020.

[6] J. L. Krok-Schoen *et al.*, ‘Increasing Adherence to Adjuvant Hormone Therapy Among Patients With Breast Cancer: A Smart Phone App-Based Pilot Study’, *Cancer Control*, vol. 26, no. 1, p. 107327481988328, Jan. 2019, doi: 10.1177/1073274819883287.

[7] F. Gambalunga, L. Iacorossi, I. Notarnicola, V. Serra, M. Piredda, and M. G. De Marinis, ‘Mobile Health in Adherence to Oral Anticancer Drugs: A Scoping Review’, *CIN Comput. Inform. Nurs.*, vol. 39, no. 1, pp. 17–23, Jan. 2021, doi: 10.1097/CIN.0000000000000643.

[8] ‘Chapter 11: Scoping reviews - JBI Manual for Evidence Synthesis - JBI Global Wiki’. Accessed: Nov. 24, 2023. [Online]. Available: https://jbi-global-wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews

[9] A. Tricco *et al.*, ‘PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation’, *Ann. Intern. Med.*, vol. 169, Sep. 2018, doi: 10.7326/M18-0850.

[10] L. A. Linder *et al.*, ‘Oral Medication Adherence Among Adolescents and Young Adults with Cancer Before and Following Use of a Smartphone-Based Medication Reminder App’, *J. Adolesc. Young Adult Oncol.*, vol. 8, no. 2, pp. 122–130, Apr. 2019, doi: 10.1089/jayao.2018.0072.

[11] A. M. Psihogios *et al.*, ‘Daily text message assessments of 6‐mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: A pilot study’, *Pediatr. Blood Cancer*, vol. 68, no. 2, p. e28767, Feb. 2021, doi: 10.1002/pbc.28767.

[12] G. Sadigh *et al.*, ‘Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study’, *J. Oncol. Pharm. Pract.*, p. 107815522311618, Mar. 2023, doi: 10.1177/10781552231161823.

[13] S. L. Spoelstra *et al.*, ‘Proof of Concept of a Mobile Health Short Message Service Text Message Intervention That Promotes Adherence to Oral Anticancer Agent Medications: A Randomized Controlled Trial’, *Telemed. E-Health*, vol. 22, no. 6, pp. 497–506, Jun. 2016, doi: 10.1089/tmj.2015.0126.

[14] B. Yanez *et al.*, ‘Rationale and usability findings of an e-health intervention to improve oral anticancer adherence among breast cancer survivors: The My Journey mindfulness study’, *Contemp. Clin. Trials Commun.*, vol. 26, p. 100898, Apr. 2022, doi: 10.1016/j.conctc.2022.100898.